Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ruprecht-Karls Universitaet maintains a patent portfolio in Biotechnology & Pharmaceuticals. The portfolio currently shows 1 pending office action. This activity is limited to 1 distinct examiner and 1 distinct art unit.
VIVLEMORE, TRACY ANN is the busiest examiner, overseeing 1 pending office action. This suggests that the university's current active prosecution in this field is focused on this technological thread, making the examiner's review central to their immediate IP objectives.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VIVLEMORE, TRACY ANN | 1 | 73.0% | +6.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16456773 | RNA VIRUSES EXPRESSING IL-12 FOR IMMUNOVIROTHERAPY | VIVLEMORE, TRACY ANN | 98d overdue |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16456773 | RNA VIRUSES EXPRESSING IL-12 FOR IMMUNOVIROTHERAPY | VIVLEMORE, TRACY ANN | 1638 | §103§112 | Non-Final OA | 98d overdue | Pending | Jun 28, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial